About US
Contact us
-
Gilead Sciences prices Sovaldi in India at a tiny fraction of U.S. costThe $84,000 U.S. treatment price that Gilead Sciences ($GILD) is charging for itshepatitis CdrugSovaldihas elicited pleas from politicians and threats from payers, who say the U.S. healthcare system c2014/8/8
-
Sanofi enlists Emcure for cancer-drug marketing in IndiaSanofi ($SNY) hasn't wasted much time dithering in emerging markets. The company spent €39 billion on deals in emerging markets over the past four years. It now has 40 manufacturing sites in emergin2014/8/7
-
U.K. cost-effectiveness watchdog bars access to AstraZeneca's IressaBacktracking on a positive decision it made four years ago, Britain's National Institute for Health and Care Excellence (NICE) has dealt a blow to AstraZeneca ($AZN) by withdrawing its endorsement of2014/8/7
-
Roche persuades U.S. judge to toss $2M Accutane verdictRoche ($RHHBY) has emerged victorious in its quest to reverse a $2.1 million verdict by a New Jersey jury in favor of a woman who blamed the Swiss pharma's acne medAccutanefor her inflammatory bowel d2014/8/6
-
Note to Big Pharma: Discounts work. GSK price cuts score Advair a payer boostGlaxoSmithKline giantAdvairmay be reeling, but it hasn't kicked the bucket yet. And now, it's getting a payer boost that will breathe a little life into falling sales. With dismal second-quarter resul2014/8/5
-
Sanofi plots FDA app for blockbuster-to-be dengue vaccine in early 2015Sanofi's ($SNY) in line to rack up blockbuster sales after hitting a wide-open market with itsdenguevaccine, analysts predict. And company CEOChris Viehbacherthinks those sales could start rolling in2014/8/4
-
Novo Nordisk more valuable than GlaxoSmithKline? That's what investors sayWho'd have thought Novo Nordisk ($NVO) could zoom past GlaxoSmithKline ($GSK) in the pharma market value rankings? Predictable or not, that's just what's happened. AsBloombergreports, Novo shares are2014/8/1
-
Craving respiratory dominance, AstraZeneca inks $2.1B deal for Almirall's lung medsAstraZeneca ($AZN) is staring down the barrel at rivals for its blockbuster respiratory drugSymbicort, branded and generic. CEO Pascal Soriot has respiratory drugs on his list of growth drivers. He's2014/7/31
-
Will he or won't he? Pfizer CEO scouts big deals, but 'silent' on AstraZeneca rebidNo news isn't good or bad for Pfizer deal-watchers. It's just no news. Anyone hoping for a halfway-clear idea of CEOIan Read's next buyout move was disappointed after Tuesday's second-quarter earnings2014/7/31
-
J&J, Pharmacyclics celebrate yet another nod for leukemia med ImbruvicaJohnson & Johnson's ($JNJ) new blood cancer drugImbruvica(ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic leukemia, adding to a series of regulato2014/7/30